Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Eledon Pharmaceuticals, Inc. (ELDN)

Eledon Q1 net loss widens to $39.0 million on $19.0 million warrant charge

Negative Impact 3 of 5 earnings Written later

Eledon Pharmaceuticals reported a first quarter 2026 net loss of $39.0 million, or $0.33 per share, up from $6.5 million, or $0.08 per share, a year earlier. The loss was driven mainly by a $19.0 million non-cash charge from changes in the fair value of warrant liabilities, and cash, cash equivalents and short-term investments fell to $111.1 million, which the company says will fund operations into 2Q 2027.

Key points

  • Net loss was $39.0 million for the quarter ended March 31, 2026, versus $6.5 million a year earlier, including a $19.0 million non-cash warrant fair value loss compared with a $10.1 million gain in 2025.
  • Excluding warrant fair value changes, the net loss was $20.1 million, compared with $16.6 million in the first quarter of 2025.
  • Research and development expenses rose to $17.2 million from $13.5 million, while general and administrative expenses fell to $4.0 million from $4.4 million.
  • Cash and short-term investments totaled $111.1 million at March 31, 2026, down from $133.3 million at December 31, 2025.

The filing

CompanyEledon Pharmaceuticals, Inc. (ELDN)
Form8-K, current report
Filed with the SECMay 13, 2026, 4:15 PM ET
Accession number0001193125-26-221658

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.